Roche moves ahead with Phase 3 Parkinson’s study despite mixed trial results

Roche and Prothena said they’re planning to proceed with a Phase 3 study of an experimental Parkinson’s antibody called prasinezumab, even though two previous mid-stage trials failed to meet their primary …